Health

Gustave Roussy Spin-Off Orakl Oncology Raises $34 Million to Predict Cancer Drug Results With AI

· 6 min read · Health

Gustave Roussy Spin-Off Orakl Oncology Raises $34 Million to Predict Cancer Drug Results With AI

Orakl Oncology, a Paris start-up spun out of the Gustave Roussy cancer centre in 2023, has raised $34 million in a Series A round to scale a platform that uses artificial intelligence to predict how experimental cancer treatments will perform, L’Agefi reported on November 12. The round was co-led by Swedish investor Norrsken VC and French venture firm Singular, with InfraVia, Serena, Bpifrance, teampact.ventures and Plug and Play also taking part. According to European Biotechnology Magazine, the round was oversubscribed and is worth about €31 million.

Orakl grows three-dimensional models of patients’ tumours in the lab, known as patient-derived organoids, and tests how they respond to drugs. It combines those results with clinical histories and molecular data to estimate how a treatment would fare before a sponsor commits to an expensive clinical trial. The company markets the prediction service as O-Predict and has named SCOPE v2 as the AI model behind it. In July it secured exclusive rights to evaluate four undisclosed Sanofi oncology assets, an early real-world test of whether its forecasts can guide drug-development decisions.

What it means in practice

Gustave Roussy Spin-Off Orakl Oncology Raises $34 Million to Predict Cancer Drug Results With AI — contextual photo

The new money brings Orakl’s total funding to $50 million, after rounds of €3 million in 2023 and €11 million in 2024. The company plans to increase its experimental data generation fivefold, move into lung and gastric cancers, set up teams in the United States and the United Kingdom, and apply its predictions to more than ten drug programmes. Norrsken says the technology can predict clinical trial outcomes with 90% accuracy, but European Biotechnology Magazine cautions that the figure rests largely on an April preprint that has not been peer-reviewed. In that study, predictions of median progression-free survival differed from published results by an average of 0.82 months, and conventional chemotherapy made up 88% of the treatment arms tested.

The deal adds to a busy autumn for French AI funding, after Bleu Robotics raised money to train factory humanoids and Nvidia lined up stakes in French start-ups including Doctolib. It also extends the use of AI against cancer beyond the hospital, where hospital networks have been sharing playbooks for imaging triage. What to watch is whether Orakl’s forecasts for the Sanofi assets hold up and whether prospective studies confirm its accuracy claims.

← Back to AI4France